Journal of Cancer Research and Clinical Oncology

, Volume 139, Issue 1, pp 147–157

Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer

  • Beatrice Detti
  • Silvia Scoccianti
  • Sara Cassani
  • Samantha Cipressi
  • Donata Villari
  • Alberto Lapini
  • Calogero Saieva
  • Tommaso Cai
  • Maurizio Pertici
  • Irene Giacomelli
  • Lorenzo Livi
  • Marco Ceroti
  • Giulio Nicita
  • Marco Carini
  • Giampaolo Biti
Original Paper

Abstract

Aim

In men with adverse pathology after radical prostatectomy, the most appropriate timing to administer radiotherapy (RT) remains a topic of debate. We analyzed in terms of efficacy, prognostic factors and toxicity the two therapeutic strategies: immediate postoperative radiotherapy (PORT) and salvage radiotherapy (SART).

Materials and methods

Between January 1995 and November 2010, 307 patients underwent adjuvant or salvage radiotherapy, after prostatectomy.

Results

In the PORT group, 42 patients (20.7 %) had biochemical failure, with a median time to biochemical failure of 1.8 years; two parameters (age at diagnosis and PSA pre-RT) resulted to be significant at the survival analysis for overall survival (p = 0.003 and p = 0.046, respectively). In the SART group, 33 patients (31.7 %) had biochemical relapse; sixteen patients died of prostate cancer; postoperative hormones therapy, conformal radiotherapy and level of PSA pre-RT >1.0 ng/ml resulted to be significant at the survival analysis, p = 0.009, p = 0.039 and p = 0.002, respectively.

Conclusion

Our study is limited by its retrospective and nonrandomized design. As such, decisions to treat with adjuvant or salvage radiotherapy and the time to initiate therapy were based on patient preference and physician counseling. Our recommendation is to suggest adjuvant radiotherapy for all patients with adverse prognostic factors and to reserve salvage radiotherapy for low-risk patients, when the biochemical recurrence occurs.

Keywords

Prostate cancer Adjuvant radiotherapy Salvage radiotherapy Prostatectomy 

References

  1. Anscher MS (2004) Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA 291:1380–1382PubMedCrossRefGoogle Scholar
  2. Anscher MS, Prosnitz LR (1991) Multivariate analysis of factors predicting local relapse after radical prostatectomy-possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 21:941–947PubMedCrossRefGoogle Scholar
  3. Bolla M, Gonzalez D, Warde P et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300PubMedCrossRefGoogle Scholar
  4. Bolla M, Van Poppel H, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial, 22911). Lancet 366:572–578PubMedCrossRefGoogle Scholar
  5. Catton C, Gospodarowicz M, Warde P et al (2001) Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59:51–60PubMedCrossRefGoogle Scholar
  6. Choo R, Danjoux C, Morton G et al (2009) Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Int J Radiat Oncol Biol Phys 75:407–412PubMedCrossRefGoogle Scholar
  7. Corn BW, Winter K, Pilepich MV (1999) Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85–31. Urology 54:495–502PubMedCrossRefGoogle Scholar
  8. Dearnaley DP, Khoo VS, Norman AR et al (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353:267–272PubMedCrossRefGoogle Scholar
  9. Geinitz H, Riegel MG, Thamm R et al (2012) Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys 82:1930–1937PubMedCrossRefGoogle Scholar
  10. Hagan M, Zlotecki R, Medina C et al (2004) Comparison of adjuvant versus salvage radiotherapy polices for post-prostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59:329–340PubMedCrossRefGoogle Scholar
  11. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European Association of Urology. Eur Urol 59:61–71PubMedCrossRefGoogle Scholar
  12. Jung C, Cookson MS, Chang SS et al (2007) Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int 99:529–533PubMedCrossRefGoogle Scholar
  13. Kaplan E, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  14. Lawton CA, Winter K, Murray K et al (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937–946PubMedCrossRefGoogle Scholar
  15. Macdonald OK, Schild SE, Fora SA et al (2004) Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 58:1530–1535PubMedCrossRefGoogle Scholar
  16. Neuhof D, Hentschel T, Bischof M et al (2007) Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 67:1411–1417PubMedCrossRefGoogle Scholar
  17. Ohri N, Dicker AP, Trabulsi EJ et al (2012) Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modeling. Eur J Cancer 48:837–844PubMedCrossRefGoogle Scholar
  18. Palisaar RJ, Graefen M, Karakiewicz PI et al (2002) Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 41:155–161PubMedCrossRefGoogle Scholar
  19. Parker C, Sydes MR, Catton C et al (2007) Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99:1376–1379PubMedCrossRefGoogle Scholar
  20. Petrovich Z, Lieskovsky G, Langholz B et al (2002) Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 53:600–609PubMedCrossRefGoogle Scholar
  21. Pettus JA, Weight CJ, Thompson CJ et al (2004) Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 172:129–132PubMedCrossRefGoogle Scholar
  22. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597PubMedCrossRefGoogle Scholar
  23. Quero L, Mongiat-Artus P, Ravery V et al (2008) Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. BMC Cancer 8:26PubMedCrossRefGoogle Scholar
  24. Schild SE (1998) Radiation therapy after prostatectomy: now or later? Semin Radiat Oncol 8:132–139PubMedCrossRefGoogle Scholar
  25. Schild SE (2001) Radiation therapy (RT) after prostatectomy: the case for salvage therapy as opposed to adjuvant therapy. Int J Cancer 96:94–98PubMedCrossRefGoogle Scholar
  26. Swanson GP, Thompson IM, Tangen C et al. (2005) Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794). Int J Radiat Oncol Biol Phys, 63(Suppl 1):A–1, S1Google Scholar
  27. Swindle P, Eastham JA, Ohori M et al (2005) Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174:903–907PubMedCrossRefGoogle Scholar
  28. Tomita N, Kodaira T, Furutani K et al (2009) Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol 135:1561–1567PubMedCrossRefGoogle Scholar
  29. Trabulsi EJ, Valicenti RK, Hanlon AL et al (2008) A multiinstitutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3−4N0 prostate cancer. Urology 72:1298–1302PubMedCrossRefGoogle Scholar
  30. Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769PubMedCrossRefGoogle Scholar
  31. Van der Kwast TH, Bolla M, Van Poppel H et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178–4186PubMedCrossRefGoogle Scholar
  32. Wheeler TM, Dillioglugil O, Kattan MW et al (1998) Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1–2 prostate cancer. Hum Pathol 29:856–862PubMedCrossRefGoogle Scholar
  33. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Beatrice Detti
    • 1
  • Silvia Scoccianti
    • 1
  • Sara Cassani
    • 1
  • Samantha Cipressi
    • 1
  • Donata Villari
    • 2
  • Alberto Lapini
    • 3
  • Calogero Saieva
    • 4
  • Tommaso Cai
    • 5
  • Maurizio Pertici
    • 1
  • Irene Giacomelli
    • 1
  • Lorenzo Livi
    • 1
  • Marco Ceroti
    • 4
  • Giulio Nicita
    • 2
  • Marco Carini
    • 3
  • Giampaolo Biti
    • 1
  1. 1.Radioterapia, Azienda Ospedaliero-Universitaria di CareggiFlorenceItaly
  2. 2.Clinica Urologica IIUniversity of FlorenceFlorenceItaly
  3. 3.Clinica Urologica IUniversity of FlorenceFlorenceItaly
  4. 4.Molecular and Nutritional Epidemiology UnitISPO (Cancer Research and Prevention Institute)FlorenceItaly
  5. 5.Department of UrologySanta Chiara HospitalTrentoItaly

Personalised recommendations